Ra Medical Systems Appoints Chief Commercial Officer

Ra Medical Systems Inc. has hired Thomas Fogarty as chief commercial officer, effectively immediately. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the company’s commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases.
 
“Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, CEO of Ra Medical Systems. “These unique characteristics make him the right fit to lead Ra Medical’s commercial efforts at such a pivotal time for our company. I believe that Tom’s results-oriented leadership approach and proven ability to ramp up sales will ultimately drive Ra Medical to the forefront of life-saving innovation as we continue to roll out our DABRA catheter and laser system around the world.”
 
Fogarty joins Ra Medical Systems from Neurvana Medical LLC, where he served as president and CEO. Over the years, Fogarty also worked at Alliance HealthCare Services Inc., Bioness Inc., and ev3 Inc. (now Medtronic) in various executive, sales and marketing roles. Earlier in Fogarty’s career, he held sales and marketing positions at Medtronic, Baxter, and Johnson & Johnson. At Bioness, Fogarty brought four new products to market and significantly increased sales over three years. At ev3 Inc., Fogarty was responsible for the development and leadership of the global commercial effort, including the launch and sales growth of several products.
 
“Joining the Ra Medical team will allow me to leverage my global commercialization experience to boost Ra Medical’s sales and further expand the company’s commercial efforts,” added Fogarty. “Having the opportunity to further this powerful mission of saving lives and limbs is a once-in-a-lifetime opportunity.”
 
Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatologic and vascular diseases. DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. DABRA quickly, photochemically dissolves plaque to the components of its fundamental chemistry. Pharos launched in 2004 and is used as a tool in the treatment of dermatological skin disorders, including psoriasis and vitiligo.